Recently, with the approval of the Ministry of Human Resources and Social Security and the National Postdoctoral Management Committee, Chengdu Jinxin Medical Investment Management Group Co., Ltd. (hereinafter referred to as “Jinxin Group”) was approved to establish a national postdoctoral research workstation.
The Zhitong Finance App learned that since 1951, Jinxin Group is a medical and health group with outstanding influence in China. The group has formed a diversified business layout such as assisted reproduction and women's full-cycle health, medical treatment, and rehabilitation, and has long insisted on the integrated development of “production, education, and research”.
According to Frost & Sullivan (Frost & Sullivan) data, its Jinxin Reproduction (01951) has the highest number of egg retrieval cycles in China. Relying on well-known medical institutions at home and abroad such as Sichuan Jinxin Xinan Women's and Children's Hospital, Shenzhen Zhongshan Obstetrics and Gynecology Hospital, and US HRC Fertility, it has built a global network of women's health and assisted reproduction services. Its business scale and service capabilities rank among the highest in the industry.
Lu Rong, general manager of Jinxin Group, said that the group is guided by clinical needs, continues to strengthen scientific research platforms and high-level talent team building, and has formed an innovative system covering basic research, clinical research, technology research and development and transformation of results.
In recent years, Jinxin Group has continued to carry out scientific research in key fields such as reproductive medicine, maternal and fetal immunity, stem cells and regenerative medicine, and genetic diagnosis. Currently, it has published more than 500 scientific research papers, set up nearly 100 projects, and won 7 national, provincial and municipal science and technology awards. It has undertaken 87 research projects in the past five years, and invested about 53 million yuan in research funding.
Currently, Jinxin Group has deployed core research platforms in Chengdu and Shenzhen, with a total area of more than 5,000 square meters. It is equipped with professional platforms such as GMP cell preparation, digital pathology, multicolor flow, protein spectroscopy and exosome testing, vivo microscopy, molecular genetic sequencing, etc., to provide favorable conditions for postdocs to carry out cutting-edge research. Currently, there are 83 full-time researchers, and high-level talents from the State Council Government, second-level professors, and outstanding talents from the Ministry of Education for the New Century, and has jointly trained 5 postdocs.
Lu Rong said that the group has established a perfect foundation for postdoctoral recruitment, training, assessment and scientific research management. After the establishment of the station, it will further rely on high-quality innovative resources from Jinjiang District and Chengdu, focus on cutting-edge fields such as reproductive medicine, maternal and fetal immunity, stem cells, and regenerative medicine, strengthen the promotion of high-level talents and collaborative innovation between industry, education, research and medicine, and promote the transformation and implementation of more scientific research results in Chengdu.